BNC KOREA, Inc.
Research BNC KOREA, Inc. (256840.KQ) on Bullrun: market cap KRW 196.98B, dividend yield 2.4%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker256840.KQ
- ExchangeKQ
- CountrySouth Korea
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyKRW
- Market capKRW 196.98B
- Dividend yield2.4%
- Financial periodQ2 2026
- RevenueKRW 24.61B
- Net income-KRW 1.13B
- Free cash flowKRW 3.33B
- Gross margin36.7%
Valuation Snapshot
latest market cap is KRW 196.98B; dividend yield is 2.4%.
Peer valuation comparison
Latest dividend yield is 2.43% versus a Healthcare sector median of 2.4%.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | KRW 196.98B | n/a | 2.4% | 70 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 70 KRW, yield 2.4%.
About BNC KOREA, Inc.
BNC KOREA, Inc. engages in the research and development, production, and sale of biomaterials for medicines in South Korea. The company offers BIENOX Inj. for temporary improvement of moderate to severe glabellar wrinkles associated with corrugator muscle and/or procerus muscle activity in adults; Juvegel for temporary improvement of moderate to severe nasolabial folds in adults; and Collapleo Plus, a collagen-based material for the supplementation of damaged or deficient ligaments, tendons, muscles, and fascia.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is BNC KOREA, Inc.'s market cap?
BNC KOREA, Inc.'s market capitalization is KRW 196.98B.
Does BNC KOREA, Inc. pay a dividend?
BNC KOREA, Inc. has a dividend yield of 2.4%.
What does BNC KOREA, Inc. do?
BNC KOREA, Inc. engages in the research and development, production, and sale of biomaterials for medicines in South Korea. The company offers BIENOX Inj. for temporary improvement of moderate to severe glabellar wrinkles associated with corrugator muscle and/or procerus muscle activity in adults; Juvegel for temporary improvement of moderate to severe nasolabial folds in adults; and Collapleo Plus, a collagen-based material for the supplementation of damaged or deficient ligaments, tendons, muscles, and fascia.